Drugs / [C-11]Methylreboxetine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04144257 | Mar 2020 → Apr 2021 | multiple sclerosis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03207464 | Oct 2017 → Dec 2026 expected | multiple sclerosis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [C-11]Methylreboxetine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03207464 ↗ |
| Modality | Diagnostic / imaging agent | “PET radiopharmaceutical.” NCT04144257 ↗ |